HemaSphere (Nov 2024)

Bortezomib before and after high‐dose therapy in transplant‐eligible patients with newly diagnosed multiple myeloma: Long‐term overall survival after more than 10 years of follow‐up from the phase III HOVON‐65/GMMG‐HD4 trial

  • Elias K. Mai,
  • Axel Nogai,
  • Henk M. Lokhorst,
  • Bronno van derHolt,
  • Sonja Zweegman,
  • Katja C. Weisel,
  • Sandra Croockewit,
  • Anna Jauch,
  • Jens Hillengass,
  • Marian Stevens‐Kroef,
  • Marc S. Raab,
  • Annemiek Broijl,
  • Gerard M. J. Bos,
  • Peter Brossart,
  • Paula Ypma,
  • Christine Hanoun,
  • Uta Bertsch,
  • Thomas Hielscher,
  • Hans J. Salwender,
  • Christoph Scheid,
  • Hartmut Goldschmidt,
  • Pieter Sonneveld

DOI
https://doi.org/10.1002/hem3.70052
Journal volume & issue
Vol. 8, no. 11
pp. n/a – n/a

Abstract

Read online

No abstracts available.